SCHEMBL6933947

SCHEMBL6933947

COC(=O)C(Cc1ccc(O)cc1)Sc1ccccc1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ESR1 P03372 1/20 0.52
ESR2 Q92731 1/20 0.52
MIF P14174 2/20 0.49
TSHR P16473 1/20 0.49
MDM4 O15151 1/20 0.49
MDM2 Q00987 1/20 0.49
NPC1 O15118 1/20 0.44
RAB9A P51151 1/20 0.44
ELANE P08246 1/20 0.44
LTA4H P09960 1/20 0.42
ESRRB O95718 1/20 0.42
CTSL P07711 2/20 0.41
OPRM1 P35372 2/20 0.41
KMT2A Q03164 1/20 0.41
NPSR1 Q6W5P4 1/20 0.41
CTSB P07858 1/20 0.41
CTSS P25774 1/20 0.41
CTSK P43235 1/20 0.41
ATM Q13315 1/20 0.41
LNPEP Q9UIQ6 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5992755 0.87 MMP8 (0.45) ESR1ESR2MIFTSHRMDM4
SCHEMBL6934672 0.83 LTA4H (0.46) RAB9ALTA4HKMT2AALDH1A1
SCHEMBL9087200 0.80 ESR1 (0.59) ESR1ESR2MIFTSHRMDM4
SCHEMBL5991888 0.78 ESR1 (0.56) ESR1ESR2MIFTSHRMDM4
SCHEMBL20664948 0.77 KMT2A (0.44) TSHRKMT2AALDH1A1
SCHEMBL6054516 0.76 ATM (0.48) MIFNPC1RAB9AKMT2AATM
SCHEMBL6933991 0.75 MMP1 (0.46) TSHR
SCHEMBL4677361 0.75 ESR1 (0.85) ESR1ESR2MIFTSHRMDM4
SCHEMBL15141727 0.73 ALPI (0.47) MDM2NPC1RAB9ACTSSCTSK
SCHEMBL3623985 0.73 MEN1 (0.44) MIFTSHRLTA4HKMT2AATM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20030212100-A1 Quinoline derivatives and medicinal use thereof MITSUI CHEMICALS, INC. (JP) 2003-11-13 US disclosed
EP-0916651-B1 PHENYLALKYLCARBOXYLIC ACID DERIVATIVES SANKYO CO (JP) 2003-10-15 EP disclosed
EP-1266888-A1 QUINOLINE DERIVATIVES AND MEDICINAL USE THEREOF Mitsui Chemicals, Inc. (JP) 2002-12-18 EP disclosed
US-6103907-A ALDOSE REDUCTASE INHIBITING ANTIDIABETIC AGENT SANKYO COMPANY, LIMITED (JP) 2000-08-15 US disclosed
CN-1219927-A Phenylalkylcarboxylic acid derivatives SANKYO CO (JP) 1999-06-16 CN disclosed
EP-0916651-A1 PHENYLALKYLCARBOXYLIC ACID DERIVATIVES Sankyo Company, Limited (JP) 1999-05-19 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030212100-A1 Quinoline derivatives and medicinal use thereof PPARG, PPARD, PPARA ESR1 944/4885ESR2 275/4885MIF 2545/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.